IMPORTANCE: No current medications improve neuropathy in subjects with Charcot-Marie-Tooth disease type 1A (CMT1A). Ascorbic acid (AA) treatment improved the neuropathy of a transgenic mouse model of CMT1A and is a potential therapy. A lower dosage (1.5 g/d) did not cause improvement in humans. It is unknown whether a higher dosage would prove more effective. OBJECTIVE: To determine whether 4-g/d AA improves the neuropathy of subjects with CMT1A. DESIGN: A futility design to determine whether AA was unable to reduce worsening on the CMT Neuropathy Score (CMTNS) by at least 50% over a 2-year period relative to a natural history control group. SETTING:Three referral centers with peripheral nerve clinics (Wayne State University, Johns Hopkins University, and University of Rochester). PARTICIPANTS: One hundred seventy-four subjects with CMT1A were assessed for eligibility; 48 did not meet eligibility criteria and 16 declined to participate. The remaining 110 subjects, aged 13 to 70 years, were randomly assigned in a double-masked fashion with 4:1 allocation to oral AA (87 subjects) or matching placebo (23 subjects). Sixty-nine subjects from the treatment group and 16 from theplacebo group completed the study. Two subjects from the treatment group and 1 from the placebo group withdrew because of adverse effects. INTERVENTIONS:Oral AA (4 g/d) or matching placebo. MAIN OUTCOMES AND MEASURES: Change from baseline to year 2 in the CMTNS, a validated composite impairment score for CMT. RESULTS: The mean 2-year change in the CMTNS was -0.21 for the AA group and -0.92 for the placebo group, both better than natural history (+1.33). This was well below 50% reduction of CMTNS worsening from natural history, so futility could not be declared (P > .99). CONCLUSIONS AND RELEVANCE: Both treated patients and those receiving placebo performed better than natural history. It seems unlikely that our results support undertaking a larger trial of 4-g/d AA treatment in subjects with CMT1A. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00484510.
RCT Entities:
IMPORTANCE: No current medications improve neuropathy in subjects with Charcot-Marie-Tooth disease type 1A (CMT1A). Ascorbic acid (AA) treatment improved the neuropathy of a transgenic mouse model of CMT1A and is a potential therapy. A lower dosage (1.5 g/d) did not cause improvement in humans. It is unknown whether a higher dosage would prove more effective. OBJECTIVE: To determine whether 4-g/d AA improves the neuropathy of subjects with CMT1A. DESIGN: A futility design to determine whether AA was unable to reduce worsening on the CMT Neuropathy Score (CMTNS) by at least 50% over a 2-year period relative to a natural history control group. SETTING: Three referral centers with peripheral nerve clinics (Wayne State University, Johns Hopkins University, and University of Rochester). PARTICIPANTS: One hundred seventy-four subjects with CMT1A were assessed for eligibility; 48 did not meet eligibility criteria and 16 declined to participate. The remaining 110 subjects, aged 13 to 70 years, were randomly assigned in a double-masked fashion with 4:1 allocation to oral AA (87 subjects) or matching placebo (23 subjects). Sixty-nine subjects from the treatment group and 16 from the placebo group completed the study. Two subjects from the treatment group and 1 from the placebo group withdrew because of adverse effects. INTERVENTIONS: Oral AA (4 g/d) or matching placebo. MAIN OUTCOMES AND MEASURES: Change from baseline to year 2 in the CMTNS, a validated composite impairment score for CMT. RESULTS: The mean 2-year change in the CMTNS was -0.21 for the AA group and -0.92 for the placebo group, both better than natural history (+1.33). This was well below 50% reduction of CMTNS worsening from natural history, so futility could not be declared (P > .99). CONCLUSIONS AND RELEVANCE: Both treated patients and those receiving placebo performed better than natural history. It seems unlikely that our results support undertaking a larger trial of 4-g/d AA treatment in subjects with CMT1A. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00484510.
Authors: J R Lupski; R M de Oca-Luna; S Slaugenhaupt; L Pentao; V Guzzetta; B J Trask; O Saucedo-Cardenas; D F Barker; J M Killian; C A Garcia; A Chakravarti; P I Patel Journal: Cell Date: 1991-07-26 Impact factor: 41.582
Authors: M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly Journal: Neurology Date: 2005-04-12 Impact factor: 9.910
Authors: P K Thomas; W Marques; M B Davis; M G Sweeney; R H King; J L Bradley; J R Muddle; J Tyson; S Malcolm; A E Harding Journal: Brain Date: 1997-03 Impact factor: 13.501
Authors: E Nelis; C Van Broeckhoven; P De Jonghe; A Löfgren; A Vandenberghe; P Latour; E Le Guern; A Brice; M L Mostacciuolo; F Schiavon; F Palau; S Bort; M Upadhyaya; M Rocchi; N Archidiacono; P Mandich; E Bellone; K Silander; M L Savontaus; R Navon; H Goldberg-Stern; X Estivill; V Volpini; W Friedl; A Gal Journal: Eur J Hum Genet Date: 1996 Impact factor: 4.246
Authors: V Timmerman; E Nelis; W Van Hul; B W Nieuwenhuijsen; K L Chen; S Wang; K Ben Othman; B Cullen; R J Leach; C O Hanemann Journal: Nat Genet Date: 1992-06 Impact factor: 38.330
Authors: P Raeymaekers; V Timmerman; E Nelis; P De Jonghe; J E Hoogendijk; F Baas; D F Barker; J J Martin; M De Visser; P A Bolhuis Journal: Neuromuscul Disord Date: 1991 Impact factor: 4.296
Authors: John Svaren; John J Moran; Xingyao Wu; Riccardo Zuccarino; Chelsea Bacon; Yunhong Bai; Raghu Ramesh; Laurie Gutmann; Daniel M Anderson; Derek Pavelec; Michael E Shy Journal: Ann Neurol Date: 2019-04-22 Impact factor: 10.422
Authors: Hien Tran Zhao; Sagar Damle; Karli Ikeda-Lee; Steven Kuntz; Jian Li; Apoorva Mohan; Aneeza Kim; Gene Hung; Mark A Scheideler; Steven S Scherer; John Svaren; Eric E Swayze; Holly B Kordasiewicz Journal: J Clin Invest Date: 2017-12-04 Impact factor: 14.808
Authors: Mario A Saporta; Vu Dang; Dmitri Volfson; Bende Zou; Xinmin Simon Xie; Adijat Adebola; Ronald K Liem; Michael Shy; John T Dimos Journal: Exp Neurol Date: 2014-10-30 Impact factor: 5.330
Authors: Nicholas E Johnson; Chad R Heatwole; Nuran Dilek; Janet Sowden; Callyn A Kirk; Denise Shereff; Michael E Shy; David N Herrmann Journal: Neuromuscul Disord Date: 2014-06-27 Impact factor: 4.296
Authors: Vera Fridman; Stefan Sillau; Gyula Acsadi; Chelsea Bacon; Kimberly Dooley; Joshua Burns; John Day; Shawna Feely; Richard S Finkel; Tiffany Grider; Laurie Gutmann; David N Herrmann; Callyn A Kirk; Sarrah A Knause; Matilde Laurá; Richard A Lewis; Jun Li; Thomas E Lloyd; Isabella Moroni; Francesco Muntoni; Emanuela Pagliano; Chiara Pisciotta; Giuseppe Piscosquito; Sindhu Ramchandren; Mario Saporta; Reza Sadjadi; Rosemary R Shy; Carly E Siskind; Charlotte J Sumner; David Walk; Janel Wilcox; Sabrina W Yum; Stephan Züchner; Steven S Scherer; Davide Pareyson; Mary M Reilly; Michael E Shy Journal: Neurology Date: 2020-02-11 Impact factor: 9.910
Authors: Megan Hwa Brewer; Ki Hwan Ma; Gary W Beecham; Chetna Gopinath; Frank Baas; Byung-Ok Choi; Mary M Reilly; Michael E Shy; Stephan Züchner; John Svaren; Anthony Antonellis Journal: Hum Mol Genet Date: 2014-05-15 Impact factor: 6.150